CJC-1295 with DAC 2MG

Product Overview

CJC-1295 with DAC 2MG is a synthetic GHRH-analogue research material containing a Drug Affinity Complex, supplied as white to off-white lyophilised powder in a 2mg catalogue presentation (SKU CD2). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

CJC-1295 with DAC was designed to extend exposure through albumin association. Research has examined GHRH-receptor signalling, pharmacokinetics and GH/IGF-axis biomarkers.

Identity and Specifications

• Product: CJC-1295 with DAC 2MG
• SKU: CD2
• Format: White to off-white lyophilised powder
• Synonyms: CJC-1295, CJC-1295 with DAC, CJC-1295 DAC
• Catalogue purity specification: ≥99%
• CAS number: 446262-90-4
• Molecular formula: C165H269N47O46
• Molecular weight: 3647.2 g/mol
• Amount: 2mg

Catalogue Distinction

This is the 2mg listing for this identity. The related CJC-1295 with DAC 5mg listing has a different labelled amount or volume and a separate SKU. The amount difference is not a dose recommendation. Unless a batch certificate states otherwise, the scientific identity and research limitations are shared while the quantity supplied differs.

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• GHRH-receptor activation
• albumin association and extended-exposure design
• growth-hormone and IGF-axis biomarkers
• peptide pharmacokinetic assay development

Evidence Quality and Limitations

The available human literature is small and early-stage. Findings cannot be interpreted as evidence of authorised use, safe administration or equivalence of this independently supplied material.

Storage and Handling

Before reconstitution: Keep the lyophilised vial sealed, dry and protected from light at −20°C, subject to the batch-specific supplier documentation. Published CJC-1295 with DAC reference data use the trifluoroacetate salt, but the counter-ion and formulation of this ExtolX batch have not been confirmed.

After reconstitution: No authoritative formulation-matched aqueous shelf life has been verified. Validate the solvent, concentration, pH, container, temperature and hold time for this batch. If the validated method supports frozen storage, use single-use aliquots and avoid repeated freeze–thaw cycles. Use clean laboratory technique, avoid vigorous agitation and record the preparation and storage history.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• Cayman Chemical: CJC-1295 with DAC trifluoroacetate storage reference
• CJC-1295 pharmacokinetic and pharmacodynamic study (PMID 16352683)
• ClinicalTrials.gov CJC-1295 study record
• CJC-1295 with DAC 5MG

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.